# Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

> **NCT00425347** · PHASE1 · COMPLETED · sponsor: **Facet Biotech** · enrollment: 35 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** HuLuc63

## Key facts

- **NCT ID:** NCT00425347
- **Lead sponsor:** Facet Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-08
- **Final completion:** 2009-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2009-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425347, "Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00425347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*